CLCN6

Across TCGA pan-cancer cohorts, CLCN6 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CLCN6 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CLCN6 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CLCN6 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, LSCC, and PDAC are the cancer types where CLCN6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	1.000	0.277	.005	22	view →
LSCC	DFS	Median	All	0.887	0.691	.008	13	view →
PDAC	OS	Median	All	0.260	0.771	.024	3	view →
GBM	DFS	Quartile	All	0.814	0.705	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CLCN6–LUAD (DFS)

Open the LUAD breakdown →